Regeneron dashes Wall Street’s hopes as COPD treatment trial suffers a failure

marketwatch.com/story/regeneron-dashes-wall-streets-hopes-as-copd-treatment-trial-suffers-a-failure-1ffb6016

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

This story appeared on marketwatch.com, 2025-05-30 19:19:00.
The Entire Business World on a Single Page. Free to Use →